Core Program

BDH-001

A fixed-dose combination cannabinoid-based analgesic with synergistic and opioid sparing effects in preclinical studies and potential for enhanced analgesia and improved safety profile, including lower risk of respiratory depression, physical tolerance/dependence, and addiction, compared to existing opioid and non-opioid analgesics. An FDA-approved cannabinoid-based analgesic would have significant advantages over current medical marijuana including available by prescription at pharmacies throughout the US including states without legal medical marijuana, coverage by pharmaceutical insurance plans, and GMP-level quality control.

The Problem:

Nearly 50 million adults in the US have significant or severe chronic pain and 25 million US adults had daily pain in the previous three months. Prescribing of opioids for chronic pain has contributed to skyrocketing rates of opioid abuse and overdose. Many pain patients have turned to medical marijuana but marijuana remains illegal at the federal level, is not available in all US states, is not FDA approved for pain or opioid use disorders, and is of variable quality due to suboptimal quality control measures. Safer and more effective medications for chronic pain are badly needed.